SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals
REGN 755.75+2.5%Nov 21 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: DewDiligence_on_SI who wrote (2089)3/29/2017 7:37:33 PM
From: Miljenko Zuanic  Read Replies (1) of 3559
 
<This, too, was covered on the CC. Once asthma is approved, they can raise the effective price by reducing the discounts/rebates when the drug is prescribed for the asthma indication.>

And you believe this? Discount/rebates are function of Rx volume? Maybe they can re-negotiate distribution of the price, but only IF there are new competitive scale (middle mans fight for profit between them), not volume increase. IMO
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News